Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia

PHASE3CompletedINTERVENTIONAL
Enrollment

500

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

August 2, 2024

Study Completion Date

December 10, 2024

Conditions
Tachycardia, SupraventricularParoxysmal Supraventricular Tachycardia
Interventions
DRUG

Etripamil NS 70 mg

Etripamil NS 70 mg will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

DRUG

Placebo

Placebo will be administered via the Aptar Pharma Nasal Spray Bidose System, supplied as prefilled devices packaged into child-resistant boxes with instructions for use provided in the study drug box.

Trial Locations (53)

100032

Beijing Anzhen Hospital; Capital Medical University, Beijing

Unknown

Baotou Central Hospital, Baotou

The First Affiliated Hospital of Baotou Medical College, Baotou

Beijing Hospital, Beijing

Beijing Tongren Hospital, Capital Medical University, Beijing

Chui Yang Liu Hospital Affiliated to Tsinghua University, Beijing

Peking Union Medical College Hospital, Beijing

The Central Hospital of China Aerospace Corporation, Beijing

The First Affiliated Hospital of Bengbu Medical College, Bengbu

The Third Xiangya Hospital of Central South University, Changsha

Xiangya Hospital, Central South University, Changsha

Changzhou No.2 People's Hospital, Changzhou

The First Affiliated Hospital of Chengdu Medical College, Chengdu

The First Hospital of Jilin University, Ch’ang-ch’un

Affiliated Zhongshan Hospital of Dalian University, Dalian

People's Hospital of Deyang City, Deyang

The First Affiliated Hospital of Fujian Medical University, Fuzhou

Nanfang Hospital of Southern Medical University, Guangzhou

Guizhou Provincial People's Hospital, Guiyang

Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou

The First People's Hospital of Hangzhou Linping District, Hangzhou

Zhejiang Provincial People's Hospital, Hangzhou

Huai'an First People's Hospital, Huai'an

Huainan First People's Hospital, Huainan

Huizhou Municipal Central Hospital, Huizhou

Jinan Central Hospital, Jinan

Shandong Province Qianfoshan Hospital, Jinan

The First Affiliated Hospital of Jinzhou Medical University, Jinzhou

Lanzhou University Second Hospital, Lanzhou

Lishui Municipal Central Hospital, Lishui

The First Affiliated Hospital of Henan Science and Technology University, Luoyang

Mianyang Central Hospital, Mianyang

The Nanchang Third Hospital, Nanchang

The Second Affiliated Hospital of Nanchang University, Nanchang

Jiangsu Province Hospital, Nanjing

Nanjing Drum Tower Hospital, Nanjing

Guangxi Zhuang Autonomous Region People's Hospital, Nanning

The second affiliated Hospital of Guangxi Medical University, Nanning

Nanyang Second General Hospital, Nanyang

Ningbo First Hospital, Ningbo

Ruijin Hospital of Shanghai Jiaotong University School of Medicine, Shanghai

Shanghai Pudong New Area People's Hospital, Shanghai

Shanghai Tongren Hospital, Shanghai

Shangrao People's Hospital, Shangrao

Shanxi Cardiovascular Hospital, Taiyuan

Jiangsu Taizhou People's Hospital, Taizhou

Binhai Hospital (Tianjin Fifth Central Hospital), Tianjin

Tianjin Medical University General Hospital, Tianjin

CR and WISCO General Hospital, Wuhan

Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan

Xingtai Third Hospital, Xingtai

The Fourth Affiliated Hospital Zhejiang University School of Medicine, Yiwu

ZiBo Central Hospital, Zibo

Sponsors
All Listed Sponsors
collaborator

Milestone Pharmaceuticals Inc.

OTHER

lead

Corxel Pharmaceuticals

INDUSTRY

NCT05410860 - Efficacy and Safety Study of Etripamil Nasal Spray Self-Administration for the Termination of Spontaneous Episodes of Paroxysmal Supraventricular Tachycardia | Biotech Hunter | Biotech Hunter